China BCT Launches New Corporate and Investor Relations Website

USA - English

• USA - English

LIUZHOU CITY, China, June 21 /PRNewswire-Asia-FirstCall/ -- China BCT Pharmacy Group, Inc., (OTC Bulletin Board: CNBI), ("China BCT" or the "Company"), a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced that it launched a new corporate and investor relations website at http://www.china-bct.com .

The new website is designed to provide a compelling platform for China BCT to communicate effectively with investors, employees, customers, suppliers, and business partners. To promote transparency, China BCT's investor relations section provides current Company information, including corporate overviews, management biographies, access to SEC filings, investor presentations, a corporate profile, press releases, and news and events.

"We are delighted to launch our new website. It is one of the most powerful and dynamic communication tools that we can leverage to engage our stakeholders with the Company," stated Mr. Hui Tian Tang, Chairman and Chief Executive Officer of China BCT. "As a public company, we are committed to cultivating a strong and responsive dialogue with our investors and provide consistent and timely business updates."

About China BCT

China BCT is engaged in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals products through its subsidiaries Guangxi Liuzhou Baicaotang Medicine Limited, Hefeng Pharmaceutical Co. Limited, and Guangxi Liuzhou Baicaotang Medicine Retail Limited in Guangxi province, China. It operates a large regional retail network in Guangxi province, consisting of 125 directly owned retail stores in Guangxi province and currently over 8,000 products are distributed through the Company's wholesale distribution network.

Safe Harbor Statement

This presentation contains "forward-looking statements" within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including the significance of the appointment of the new directors. Accordingly, although the Company believes that the expectations reflected in such forward- looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this presentation.

    For more information, please contact:

    Company Contact:
     Ms. Shelly Zhang, Chief Financial Officer
     China BCT Pharmacy Group, Inc.
     Phone: +86-772-363-8318
     Email: [email protected]

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Phone: +1-646-213-1915
     Email: [email protected]

     Mr. Shaun Smolarz, Financial Writer
     Phone: +1-646-701-7444
     Email: [email protected]
     CCG Investor Relations
     Web:   http://www.ccgirasia.com

SOURCE China BCT Pharmacy Group, Inc.